Patents by Inventor Donna L. Romero

Donna L. Romero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USP30 inhibitors and uses thereof
    Patent number: 11845724
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 19, 2023
    Assignee: Vincere Biosciences, Inc.
    Inventors: Donna L. Romero, Michael Garrett Johnson, Andrew David Lee, Bahareh Behrouz, Edward Lawrence Fritzen, Jr.
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230391797
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: December 23, 2022
    Publication date: December 7, 2023
    Inventors: Markus DAHLGREN, Jeremy Robert Greenwood, Geraldine c. Harriman, Joshua Jahmil Kennedy-Smith, Craig E. Masse, Donna L. Romero, Mee Shelley, Ronald T. Wester
  • COMPOUNDS AND METHODS FOR TREATING DISEASE
    Publication number: 20230374058
    Abstract: The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.
    Type: Application
    Filed: July 26, 2023
    Publication date: November 23, 2023
    Inventors: Donna L. ROMERO, Oliver Saunders, Gregory Stuart Bisacchi, Dennis Zaller, Rosana Kapeller-Libermann
  • Inhibitors of Dihydroceramide Desaturase For Treating Disease
    Publication number: 20230357187
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 9, 2023
    Inventors: Donna L. Romero, Jeremy Blitzer
  • HETEROARYL INHIBITORS OF PDE4
    Publication number: 20230348501
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 2, 2023
    Inventors: Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
  • Inhibitors of dihydroceramide desaturase for treating disease
    Patent number: 11771684
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: October 3, 2023
    Assignee: Centaurus Therapeutics
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • Heteroaryl inhibitors of PDE4
    Patent number: 11767334
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: September 26, 2023
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • COMPOUNDS AND METHODS FOR TREATING DISEASE
    Publication number: 20230295212
    Abstract: The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 21, 2023
    Inventors: Donna L. ROMERO, Oliver SAUNDERS, Gregory Stuart BISACCHI, Dennis ZALLER, Rosana KAPELLER-LIBERMANN
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230074228
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: July 20, 2022
    Publication date: March 9, 2023
    Inventors: Craig E. MASSE, Jeremy Robert GREENWOOD, Donna L. ROMERO, Geraldine C. HARRIMAN, Ronald T. WESTER, Mee SHELLEY, Joshua Jahmil KENNEDY-SMITH, Markus DAHLGREN, Sayan MONDAL, Shaughnessy ROBINSON
  • Inhibitors of dihydroceramide desaturase for treating disease
    Patent number: 11597715
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 7, 2023
    Assignee: Centaurus Therapeutics
    Inventors: Donna L. Romero, Jeremy Blitzer
  • HETEROARYL INHIBITORS OF PDE4
    Publication number: 20230024240
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: June 23, 2022
    Publication date: January 26, 2023
    Inventors: Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
  • USP30 INHIBITORS AND USES THEREOF
    Publication number: 20220315531
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 6, 2022
    Inventors: Donna L. ROMERO, Michael Garrett JOHNSON, Andrew David LEE, Bahareh BEHROUZ, Edward Lawrence FRITZEN, Jr.
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11459307
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: October 4, 2022
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • TYK2 inhibitors and uses thereof
    Patent number: 11434240
    Abstract: The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: September 6, 2022
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Donna L. Romero, Geraldine C. Harriman, Ronald T. Wester, Mee Shelley, Joshua Jahmil Kennedy-Smith, Markus Dahlgren, Sayan Mondal, Shaughnessy Robinson
  • Heteroaryl inhibitors of PDE4
    Patent number: 11401286
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 2, 2022
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
    Publication number: 20220079926
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 17, 2022
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11191765
    Abstract: Disclosed herein are new heterocyclic compounds and compositions having structural Formula (I) and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: December 7, 2021
    Assignee: BioEnergenix LLC
    Inventors: John McCall, Robert C. Kelly, Donna L. Romero
  • Inhibitors of dihydroceramide desaturase for treating disease
    Patent number: 11135207
    Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 5, 2021
    Assignee: Centaurus Therapeutics
    Inventors: Donna L. Romero, John M. McCall, Jeremy Blitzer
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20210238198
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: February 16, 2021
    Publication date: August 5, 2021
    Inventors: Markus Dahlgren, Jeremy Robert Greenwood, Geraldine C. Harriman, Joshua Jahmil Kennedy-Smith, Craig E. Masse, Donna L. Romero, Mee Shelley, Ronald T. Wester
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20210198216
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: August 12, 2020
    Publication date: July 1, 2021
    Inventors: John M. MCCALL, Donna L. ROMERO, John MCKEARN, Michael CLARE